Work

Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma

Year: 2025

Type: supplementary-materials

Abstract: Supplemental Table 2. Representativeness of Study Participants.

DOI: 10.1158/1078-0432.28431612

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4407629249

Cites:

Cited by:

Related to: 2